The European study is expected to enroll 40 newly diagnosed AML patients. ・Enrollment at U.S. sites is planned to begin in ...

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

$SLS insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales. Here’s a ...

As of Friday, January 02, SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 23.08%, which has investors ...

SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares are trading higher on Monday after initially dropping in premarket trading, reversing course as investors seem to react to new trial‑related updates ...

Sellas Life Sciences Group Inc (NASDAQ:SLS) stock surged 16.9% on Monday after the company provided an update on its Phase 3 REGAL trial evaluating GPS as a maintenance therapy for acute myeloid ...

SELLAS Life Sciences (NASDAQ:SLS) traded sharply lower on Thursday after the New York-based biotech released interim results from its Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS), ...